icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TABRECTA (capmatinib).
Voir aussi
Décision d'accès précoce
05/08/2022
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
NAkRLQDpJh95enbf